Vanguard Investments Australia
AVBP icon

Vanguard Investments Australia’s ArriVent BioPharma AVBP Stock Holding History

Vanguard Investments Australia’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
6,077
– – ﹤0.01% 2088
2026
Q1 		$140K Buy
+6,077
New +$137K ﹤0.01% 2183

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Investments Australia's AVBP Position: Q2 2026 in Review

Vanguard Investments Australia held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 6,077 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Vanguard Investments Australia first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Vanguard Investments Australia held 6,077 shares of ArriVent BioPharma worth $211K as of Q2 2026.
  • Vanguard Investments Australia left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2088 holding.
  • Vanguard Investments Australia first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.